Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers Worldwide.

Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers Worldwide.
Antimicrob Agents Chemother. 2020 Sep 08;:
Authors: Sader HS, Duncan LR, Arends SJR, Carvalhaes CG, Castanheira M
Abstract
Aztreonam-avibactam was tested against 1,839 Stenotrophomonas maltophilia collected worldwide and demonstrated potent activity against isolates from all geographic regions and infection types (overall MIC50/90, 4/4 mg/L; 97.8% inhibited at ≤8 mg/L). Trimethoprim-sulfamethoxazole (TMP-SMX; MIC50/90, ≤0.5/1 mg/L; 95.4% susceptible) and minocycline (MIC50/90, 0.5/2 mg/L; 99.5% susceptible) also were very active. Aztreonam-avibactam inhibited 84.7% of TMP-SMX-nonsusceptible isolates at ≤8 mg/L. Aztreonam-avibactam may represent a valuable option to treat S. maltophilia infections, addressing a major unmet medical need.
PMID: 32900683 [PubMed - as supplied by publisher]

Source: Antimicrobial Agents and Chemotherapy - September 7, 2020 Category: Microbiology Authors: Sader HS, Duncan LR, Arends SJR, Carvalhaes CG, Castanheira M Tags: Antimicrob Agents Chemother Source Type: research